Trial Information - Phase N/A
KRAS DetECT: KRAS mutation Detection to Evaluate Eligibility for Clinical Trials
Disease Specifics: (NSCLC)
Protocol ID: MA-MRTX-100
Sponsor: Mirati Therapeutics Inc.
Status: OPEN TO ENROLLMENT
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
